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SUMMARY 
We have attempted to produce the 13%kDa early protein (ep138) of Epstein-Barr virus (EBV) in Escherichia 
coZi. This protein was found, by immunoprecipitation, to be a clinically relevant antigen, especially for the 
determination of the IgA-titer in patients with nasopharyngeal carcinoma (NPC). Since the expression of the 
entire ep138 coding region was unsuccessful, we synthesized only the antigenic parts of this protein. Potential 
antigenic sites were predicted from the amino acid sequence by combining values for hydrophilicity with 
calculated estimates of the secondary structure. The two predicted fragments were found to be antigenic, but 
only one of them was stably expressed in E. coli as a non-fusion protein. This stable protein fragment was, in 
turn, able to stabilize the second antigenic fragment forming an autologous fusion protein, consisting exclusively 
of EBV-derived sequences. The resulting product reacts particularly well with IgA antibodies of NPC patients 
indicating its diagnostic value for NPC. 
* To whom correspondence and reprint requests should be ad- 
dressed. 
Abbreviations: aa, amino acid(s); Ap, ampicillin; bp, base 
pair(s); d, deletion; EA, early antigen; ELISA, enzyme-linked 
immuno-sorbent assay; EBV, Epstein-Barr virus; ep138, 138- 
kDa early protein of EBV; FR. followed by roman numbers, 
DNA-fragment(s); BGal, bgalactosidase; Ig, immunoglobulin; 
IPTG, isopropyl-PDo-thiogalactoside; IacZa, part of 1acZ coding 
for a peptide; LB, Luria broth; NPC, nasopharyngeal carcinoma; 
A, absorbance at 600 nm; oligodnt, oligodeoxynucleotide; ORF, 
open reading frame; PA, polyacrylamide; PAGE, PA gel electro- 
phoresis; SDS, sodium dodecyl sulfate; VCA, virus capsid 
antigen; XGal, 5-bromo-4-chloro-indolyl-r%-galactoside; : : , 
novel joint. 
INTRODUCTION 
Epstein-Barr virus (EBV) can cause infectious 
mononucleosis after primary infection and is strong- 
ly linked to the undifferentiated form of NPC and as 
an etiologic factor to African Burkitt’s lymphoma. In 
some areas of Southern China, Singapore and Ma- 
laysia, NPC is the most frequent neoplasia with an 
incidence of up to 40 cases per 100000 inhabitants 
per year. Early detection is particularly important 
because this tumor responds very well to radiothera- 
py in the early stages (survival rates up to 93% in 
stage I and 75 y0 in stage II) and dramatically less in 
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more advanced stages. Although EBV DNA can be 
demonstrated in tumor cells of all NPC biopsies 
tested, this approach is not feasible for mass 
screening for an early detection of this tumor. Prior 
to the onset of tumor formation elevated titers of IgG 
and IgA antibodies to the viral capsid antigens and 
early antigens have been described for NPC patients. 
Field studies have already demonstrated the value of 
serological screening (Zeng et al., 1985). (For refer- 
ences on the EBV-related diseases and diagnosis see 
Simons and Shanmugaratnam, 1982.) 
Mass screening of the high-risk groups would be 
possible if inexpensive and automat-readable tests 
were available. When partially purified antigens from 
EBV-producing cell cultures are used, tests are prone 
to background reactions and are expensive. There- 
fore we decided to produce an EBV-related antigen 
by gene technological methods and use it in an 
ELISA. This should result in higher sensitivity and 
provide a low-cost, rapid screening system for the 
early detection of NPC and also for the diagnosis of 
other EBV-related diseases. 
We describe approaches for the expression of 
ep 138, which belongs to the early antigen group in 
the lytic EBV infection. This protein is known to be 
a major DNA-binding protein which shares homol- 
ogies to the ICP8 from HSVl (D. McGeoch, R.S. 
and H.W., unpublished). We selected the ep138 for 
several reasons: after induction of EBV-infected 
cells the ep138 is one of the most abundant early 
proteins (Bayliss and Wolf, 1981); sera from differ- 
ent NPC-patients contain antibodies against this 
protein (Wolf et al, 1984); the coding region was 
located in the BamHI-A fragment in an area with 
appropriate reading frames (Seibl and Wolf, 1985). 
proA+ B +, fucZqZAM15]} (Yanisch-Perron, et al., 
1985) and plasmids pUC8, pUC9, pUC13 (Vieira 
and Messing, 1982), pEA305 (Amann et al., 1983), 
pKK240-11 (Amann and Brosius, 1985), pUR278, 
pUR288 (RUther and MUller-Hill, 1983) and pINIII- 
Al (Masui et al., 1984) were used. 
(b) DNA-sequences and computer programs 
The sequence of the BamHI-A fragment was 
obtained from B. Barrel1 (Baer et al., 1984) prior to 
publication. For searching restriction enzyme sites, 
reading frames and maps the UWGCG programs 
(Devereux et al., 1984) were used. 
The program for the prediction of antigenic sites 
by calculating the secondary structures superimpos- 
ed with values for hydrophilicity was developed in 
our laboratory for the VAX750 on the basis of a 
program written by E. Golub (Cohen et al., 1984). 
Our program was written to function as a subpro- 
gram of the UWGCG software and can therefore 
directly use sequences from the major protein or 
nucleic acid libraries. 
(c) Induction and analysis of expression products 
Overnight cultures of clones containing the desir- 
ed plasmids were grown in LB-medium containing 
50 pg Ap/ml. They were diluted to an A = 0.3; when 
the A reached 0.7, IPTG was added to give a final 
concentration of 1 mM and the cultures were incu- 
bated for another 2 h. Cell pellets from 1.5 ml culture 
were lysed in 150 ~1 of sample buffer (Laemmli, 
1970), boiled for 5 min and lo-25 ~1 of the lysate 
were separated by SDS-PAGE and evaluated after 
staining with Coomassie blue. 
(d) Detection of EBV-related antigenic proteins 
MATERIALS AND METHODS 
(a) Bacterial strains and plasmids 
The BamHI-A fragment of EBV containing the 
region coding for ep138, cloned into the BamHI site 
of pBR322, was obtained from J. Skare (1980). For 
cloning and expression procedures E. coli strain 
JM83 {ara, A(fuc-proAB), strA, ZucZAM15,~80}, 
and JM109 (recA1, endA 1, gyrA96, thi, hsdR17, 
.supE44, relA 1, 2 -, A(luc-proAB), [F’, traD36, 
After SDS-PAGE the proteins of the bacterial 
lysates were transferred onto nitrocellulose (Bur- 
nette, 198 1). The nitrocellulose filter was preadsorb- 
ed for 2 h with a modified 5 x Denhardt’s solution 
(Denhardt, 1966) supplemented with 0.1% Nonidet 
P-40, 1.5% bovine serum albumin, 170 mM borate, 
150 mM NaCl, 0.25% gelatine and 0.04% NaN, 
(Cohen et al., 1984) and incubated overnight at room 
temperature with a 1 : 50 diluted high-titered NPC 
serum pool (EA 1 : 1200, VCA 1 : 6600) or individu- 
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al sera which were previously preadsorbed with bac- 
terial lysates. After washing with gelatine buffer 
(50 mM Tris. HCl, pH 7.5, 5 mM Na,. EDTA, 
150 mM NaCl, 0.25% gelatine, 0.5% Triton X-100, 
0.1% SDS) the bound antibodies were incubated 
with peroxidase-conjugated anti-human IgG or IgA 
rabbit antibodies (Dako) and stained with 0.0 1 y0 
H,O, and 0.5 mg/ml diaminobenzidine (Sigma). 
RESULTS AND DISCUSSION 
(a) Localization of the ORF coding for ep138 
According to the mapping data obtained by hyb- 
rid-selected translation of mRNA from induced 
P3HRl cells probed with cloned BamHI fragments, 
the coding region for the ep138 is located in the 
BamHI-A fragment at the right end of the viral 
genome (Seibl and Wolf, 1985). Three leftward 
oriented large ORFs can be identified from the 
sequence data. Although splice events cannot be 
excluded, an ORF at the right end of the BumHI-A 
(BALF2 according to Baer et al., 1984) was the right 
size to encode the ep138. To test our assumption, we 
inserted a 3.0-kb XhoI fragment spanning this ORF 
into pUC8 and used the resulting plasmid, pUC635, 
as a probe for a hybrid-selected translation of 
mRNA from induced P3HRl cells. Fig. 1 gives an 
overview on the localization of epl38-encoding 
sequences used for the engineering to obtain 
pUC635 and other clones described in the following. 
Fig. 2 shows that ep138 is encoded by this ORF, 
with 1128 aa and a calculated M, of 123 027. 
(b) Synthesis of large segments of ep138 
We used the pUC plasmid vectors, which have 
previously been used to express eukaryotic proteins 
in E. coli (e.g., Guise et al., 1985) or vectors with tuc 
promoters (DeBoer et al., 1983). In addition to 
pUC635 (also used for mapping), three other plas- 
mids with large fragments of the ep138 coding region 
were derived (pUC924, pMF924 and pKK378; 
Fig. 1; vectors and details of construction see legend 
Fig. 3) and tested for production of an EBV-related 
antigen. 
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Fig. 1. The ORF encoding epl38 of EBV strain B95-8 (open bar) and localization of restriction sites used for the construction of 
subclones indicated in the lower part. The HgiAI site at the N-terminus cleaves in the sequence encoding aa No. 3. The second XhoI 
site is located two aa upstream of the stop codon of ep138. The third XhoI site is 250 bp downstream. pUC635 (used for hybrid-selected 
translation), pKK378, pUC924 and pMF924 encode large segments of ep138. Their construction is given in legend of Fig. 3. The 




Fig. 2. In vitro translation of mRNA from induced P3HRl cells 
after hybrid selection with pUC635 (right lane) and unselected 
total RNA as control (left lane). The position ofep138 (138 kDa) 
and of two other proteins, which belong to the VCA group 
(Bayliss and Wolf, 1981). are indicated (sizes in kDa). To select 
mRNA, 8 pg of pUC635 was sheared by sonication and spotted 
to 5 x 5 mm nitrocellulose filter. After washing and baking at 
80°C for 2 h, 100 pg RNA from induced P3HRl cells (induction 
of P3HRI with 40 ng/ml phorbol-12-myristate-13-acetate and 
3 mM butyric acid for three days) was hybridized to the filter. 
Bound mRNA was eluted by boiling, precipitated with ethanol 
and translated with a mRNA dependent rabbit reticulocyte ly- 
sate in the presence of [35S]methionine as described earlier 
(Seibl and Wolf, 1985). For translation of unselected RNA, 7 ng 
were added to the translation assay. The labeled proteins were 
mixed with immunoprecipitation buffer (1 y0 Triton X-100,0.1 Y0 
SDS, 0.137 M NaCl, 1 mM CaCI,, 1 mM MgCl,, 10’4 glycerol, 
All the expression-plasmid-produced segments of 
ep138 were in the expected M, range, but the yield 
was low and varied widely. The fusion proteins en- 
coded by the constructs pUC635 and pMF924 seem 
to give better expression in a more stable fashion 
than the non-fusion proteins from pUC924 and 
pKK378. The antigen yield from pUC635, which 
gave the highest expression, was far too low for 
large-scale production. A reproducible expression 
was only possible with the k-repressor protein 
overproducer recA _ strain JM 109. Apparently the 
ep138 is toxic to the bacterial cells, perhaps, due to 
its proposed DNA-binding capacity (Roubal et al., 
198 1). A similar result was obtained with the expres- 
sion of ICP8 of HSVl (Pearson et al., 1985), which 
seems to have the same DNA-binding function and 
shares homologies to the protein sequence of ep 138. 
(c) Computer-predicted localization of antigenic 
sites 
In the ELISA the presence of antigenic sites is 
important and not the entire protein. Since the ex- 
pression of large parts of ep138 is diflicult and inef- 
ficient, we decided to express only small antigenic 
peptides from ep138. Antigenic sites are often as- 
sumed to be in hydrophilic areas. The examination 
of hydrophilicity plots, however, did not allow the 
identification of appropriate sites for a promising 
sub-genomic expression cloning. Based on the as- 
sumption that antigenic sites are mainly located wi- 
thin hydrophilic /?-turns, we used a computer pro- 
gram, which superimposes the data for hydrophilici- 
ty (Hopp and Woods, 1981) upon the secondary 
structures predicted from the algorithms of Chou 
and Fasman (1974a,b) and Argos et al. (1978) 
(Fig. 4). A similar program was successfully used for 
predictions of antigenic sites in gpB from HSVl 
(Cohen et al., 1984). Our program was tested for its 
validity with the polio virus VP 1, where the antigenic 
sites were mapped by synthetic peptides or monoclo- 
20 mM Tris HCI, pH 9.0, 0.01 Y0 NaN, and 1 mM phenylme- 
thyl-sulfonyl fluoride) and incubated with 5 ~1 each of the NPC 
serum pool (preadsorbed with a protein extract from EBV-nega- 
tive BJA cells). Immune complexes were bound to protein A- 
sepharose, washed, eluted by boiling and fractionated by 
SDS-12”; PAGE. The gel was dried and exposed to a X-ray 
film. 
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Fig. 3. Expression of major fragments of ep138 in E. coli. The 
proteins of IPTG-induced JM 109 cells carrying plasmids indicat- 
ed on top were separated on a SDS-IO% PA gel and transferred 
to nitrocellulose. EBV-related proteins were visualized by immu- 
nostaining with the NPC serum pool; human sera show a moder- 
ate reaction with E. coli proteins which results in background 
bands. In the left lane proteins from cells carrying pUC8 were 
applied as a control. Sizes on the left margin are in kDa. The 
DNA fragments used for the construction of these clones and 
their location on the ep138 encoding region is shown in Fig. 1. 
pUC924 contains the 2.6-kb fragment from the BglII site to the 
third XhoI site, the translational stop codon from ep138 should 
be used and the resulting non-fusion protein has a size of about 
80 kDa. The plasmid pMF924 was constructed from pEA305 
(Amann et al., 1983) and the same EglII-XhoI fragment as in 
pUC924. pEA305 has a tat promoter followed by the N-terminal 
part of the cI857-coded i, repressor, hence the resulting fusion 
protein is 17 kDa larger than from pUC924. The plasmid 
pUC635 has an insert corresponding to aa 108 up to aa 1127, the 
aa immediately before the stop codon ofep138. The 3.05kbXho1 
fragment was inserted into the Sal1 site of pUC8 and the reading 
frame of the pUC-encoded IacZa fits with the ep138 ORF at the 
5’ and the 3’ end. The resulting expression product is a fusion 
protein with 11 aa at the N-terminus and 1 I kDa of the IucZa. 
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nal antibodies (Jameson et al., 1984). The computer 
predictions agree very well with the recently deter- 
mined X-ray crystallographic data (Hogle et al., 
1985). 
This approach suggested the presence of two ma- 
jor potential antigenic epitopes (Fig. 4) one located 
around aa 520 (FR.IV) and the other close to the 
C-terminus of ep 138 (FR.VII). 
(d) Subcloning and expression as j?Gal fusion pro- 
teins of DNA fragments encoding segments of ep138 
To test the computer-aided localization, we exam- 
ined segments of ep138 for antigenicity. Since most 
eukaryotic protein segments are degraded immed- 
iately after synthesis in bacteria, fusion proteins with 
the large bacterial /?Gal were constructed to protect 
the ep138 protein segments from proteolysis. The 
DNA fragments corresponding to the protein seg- 
ments indicated in Fig. 4 were subcloned from the 
BarnHI-A fragment and pUC635 and inserted at the 
3’ end of the ZucZ gene of the pUR-vectors (Ruther 
and Mtiller-Hill, 1983). Fig. 5, left panel, shows the 
expression of the resulting fusion proteins with the 
various ep138 segments. The immunostained Wes- 
tern blot, using pooled human sera from NPC 
patients, allows the identification of antigenic ep138 
segments (Fig. 5, right panel). As predicted by our 
computer program, only the fusion proteins from 
clones pUR600 and pUR540 carrying FR.IV and 
FR.VII, respectively, react as EBV-specific antigens. 
(e) Expression of the subfragments in pUC plasmid 
vectors 
Due to the presence of antibodies in human sera 
specific for bacterial proteins, the use of BGal fu- 
sion proteins in ELISA may give erroneous results. 
Therefore, we tested whether the pUC clones used 
for the construction of the pUR plasmids (see legend 
Fig. 5) would produce stable products. In these pUC 
clones the ORFs of the inserts (FR.I-FR.VII) are in 
The insert of pKK378 starts at the same XhoI site and continues 
to the third XhoI site located 250 bp 3’ of the stop codon. The 
3.3-kb fragment was inserted 3’ of the tat promoter and the start 
codon of pKK240-11. The expression product contains only two 







Fig. 4. Computer plot of the predicted secondary structure of ep138 aa sequence. The dark line represents the aa backbone (numbers 
indicate aa positions) with the probable x-helices, /?-sheets, coil-structures (barely discernable in the scale used) and /?-turns (line turn 
of 180”). Hydrophilic areas are given as circles, hydrophobic as diamonds (maximum values from - 3 to + 3 indicated are aa in stretches 
with averages over k 0.9, calculated for 7 aa). The DNA fragments FR.1 to FRVII used for subcloning and examination for antigenic 
sites (see legend Fig. 5) encode the indicated protein segments. Strong hydrophilic loop structures can be seen around aa 520 (encoded 
by FR.IV) and near the N-terminus (FR.VII). In these regions an antigenic reaction could be expected. 
frame with the pUC-encoded 1ucZsl at their 5’ and 
3’ ends. Therefore the expression products are 
fusion proteins with a small 1 1-kDa flGa1 fragment 
at the C-terminus. Only the plasmid pUCP600, car- 
rying the FR.IV-fragment (Fig. 4), expresses an ad- 
ditional polypeptide of about 32 kDa resulting from 
transcription and translation of the 600-bp of FR.IV 
(21 kDa) and the 1acZcr (11 kDa) (Fig. 7, pUCP600 
lanes, PA gel of the pUC constructs with 
FR.I,II,III,V,VI and VII not shown). In an immu- 
noblot with the NPC serum pool this protein gives a 
stronger signal than the corresponding pUR clone, 
suggesting that the epitope in the large fusion product 
is partially hidden by the large /IGal. The instability 
of the translation products from pUC vectors carry- 
ing the other DNA fragments of the ep138 coding 
region is not too surprising since the products are 
small protein segments which might not fold such 
that they are protected from proteolytic degradation. 
When the E. coli strain JM83 was transformed with 
the pUC-derived plasmids, all transformed colonies 
on agar plates containing XGal and Ap appeared 
light blue. Strain JM83 does not overproduce the lac 
repressor and needs the N-terminal part of the fiGa 
encoded by the pUC plasmid for the a-complemen- 
tation of its partially deleted genomic 1acZ gene. The 
light blue color indicates that the ORF of the pUC- 
encoded 1ucZ from the initiation codon through the 
inserted fragment is transcribed and translated. This 
finding suggests that all subfragments are expressed, 








Fig. 5. Expression ofep138 segments as fiGa fusion proteins and localization ofantigenic sites. The proteins ofthe IPTG-induced clones 
indicated on top of each lane were analysed by SDS-lo% PAGE and Coomassie blue staining (left panel). In comparison to the BGal 
encoded by pUR288, the fiGa : ep138 fusion proteins (black dots) have an increased M, depending on the DNA insert size (bp 
correspond to clone numbers). The right panel shows the same SDS-PA gel after Western blotting and immunostaining with the NPC 
serum pool. As predicted by the computer drawings (Fig. 4) the fragments FRIV in pUR600 and FR.VII in pUR540 encode protein 
segments which were recognized by the human immune system. The HgiAI-PsrI fragment (FR.1, Figs. 1 + 4) was cloned from BarnHI-A 
into pUC9 to yield pUCHP, isolated from this plasmid as EcoRI-Hind111 fragment and inserted into pINIIIA1. With this procedure 
a second BanrHI site (besides the one originated from pUC9) was generated next to the Hind111 site. From a resulting clone the FR.1 
was excised with BumHI and inserted into pUR288 to yield pURHP. pUR400 carrying FR.11 was obtained from pUC635 digested 
with PsrI, religation (pUCP400) and insertion of FRII as BumHI-Hind111 fragment into pUR288. The constructs pUR380 (FRIII), 
pUR600 (FRIV), pUR210 (FR.V), pUR750 (FR.VI) and pUR540 (FR.VII) were achieved by insertion of PstI fragments of pUC635 

















CGT CGT CGT CGT CGT TGA TA 
GCA GCA GCA GCA GCA ACT ATT CGA 
Arg ArQ Arg Ars Arg stop stop 
Fig. 6. Construction of the plasmid pUCARGl140 encoding 
both antigenic sites found by expression as BGal fusion proteins. 
(1) Scheme of the cloning procedures. Using a SstI site which is 
located 25 bp from the 5’ PstI site (Fig. 1), FrIV of pUCP600 
was isolated as SstI-Hind111 fragment and inserted into pUCl2 
(pUC601). Between the PsfI and Hind111 sites of this plasmid the 
oligodnt [see (2) below] was inserted to yield pUCARG601. The 
fragment FR.VII encoding the second antigenic site was 
integrated as Pstl fragment derived from pUCP540. E, EcoRI; B, 
BumHI; S, SalI; Ps, &I; Ss, SstI; H, HindHI; PO and heavy 
arrow, lucZUV5 promoter and operator of the pUC plasmids; 
open segment, ep138 encoding sequences; shaded segment, 
synthetic oligodnt. (2) Nucleotide sequence of the oligodnt 
coding for live arginine residues and two stop codons when 
inserted into pUC601. The lower strand was synthesized and 
inserted as single-stranded DNA between the sticky ends of PstI 
and Hind111 via bridge formation, ligation and transformation 
into E. roli JM109. The correct integration was proved through 
sequence analysis (not shown). 
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(f) Combination of the two antigenic sites and in- 
sertion of an oligodeoxynucleotide encoding oligo- 
arginine 
DNA fragments FR.IV and FR.VII were combin- 
ed in frame on one plasmid to obtain an ORF encod- 
ing both antigenic regions found in ep138. To prev- 
ent translation of vector-encoded sequences, a syn- 
thetic oligodnt coding for two translational stop 
codons was inserted at the 3’ end of the ORF. The 
oligodnt further codes for five arginine residues 5’ of 
the stop codons. The resulting construct 
(pUCARG1140) codes for a protein consisting of 
the two antigenic epitopes with five arginine residues 
at the C-terminus. The protein segment encoded by 








in the pUC expression, is now stabilized by the 
peptide encoded by FR.IV. The additional arginine 
residues may be useful for the purification following 
a procedure of Sassenfeld and Brewer (1984). The 
sequence of the oligodnt and the construction 
scheme for pUCARG 1140 is given in Fig. 6 and the 
expression products of the various constructs leading 
to pUCARG1140 are shown in Fig. 7. 
The combination of the two antigenic sites was 
necessary to cover the spectrum of antibodies direct- 
ed against ep138, since the immunological reactions 
differ in the various patients (Fig. 8). Whereas in 
NPC serum No. 352 the main fraction of the IgG 
and IgA antibodies is directed against the epitope 
encoded by FR.VII, the reaction in NPC serum 
No. 354 shows the reverse pattern. A representative 
Fig. 7. Expression in pUC plasmids of antigenic segments ofepl38. Proteins of IPTG-induced clones carrying pUC plasmid constructs. 
described in legend of Fig. 6 and indicated on top, were analysed through SDS-17% PAGE and Coomassie blue staining (left panel). 
EBV-related expression products are indicated by arrowheads. The right panel shows the same SDS-PA gel after Western blotting 
and immunostaining with the NPC serum pool. In comparison to pUCP600, the M, of the protein encoded by FR.IV is decreased by 
about 1.5 kDa in pUC601 due to the lack of 14 aa (6 aa encoded by the pUC polylinker and 8 aa from the deleted MI-SstI sequence 
in FRIV). The size of the protein encoded by pUCARG601 is further reduced by about 11 kDa since read-through into the IacZa of 
pUC is inhibited by the stop codons inserted with the oligoArg-coding oligodnt. In pUCARGll40 the size increases to about 42 kDa 
due to the insertion of FR.VII (540 bp). 
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~~~352 NPC3!54 
Fig, 8. Distribution and reactivity of the IgG and IgA antibodies of individual NPC sera against the two antigenic regions detected in 
epl38. Aliquots of IPTG-induced clones were separated through SDS-12% PAGE and transferred onto nitrocellulose filters. Two 
individual NPC-sera (Nos. 352 and 354) were incubated with the filters and the IgG and IgA antibodies bound were visualized with 
peroxidase conjugated anti-human IgG and anti-human IgA rabbit antibodies through peroxidase reaction. Lanes 1: pUR288 as negative 
control; lanes 2: pUCARGll40 as a positive control; lanes 3: pUR540; lanes 4: pUR600. The differentM,s, especially for pUCARGl140, 
result from different running times ofthe SDS-PAGE. The main reaction ofthe IgG and IgA antibodies in NPC serum No. 352 is directed 
against the fusion protein encoded by pUR540 with the antigenic region from the C-terminus of ep138 (FR.VII). In serum No. 354 the 
majority of the antibodies recognizes the antigenic site encoded by pUR600 (FRIV), indicating that both protein segments are necessary 
for detecting all anti-ep138 antibodies in sera. 
pool prepared from many sera of NPC patients did 
not detect additional antigenic sites (Fig. 5). These 
data imply that both antigenic sites are necessary 
and sufficient to obtain the desired specificity in 
the ELISA usable for diagnostic purpose. 
A partially purified preparation of the pUCARG- 
1140-encoded protein was used to immunize rabbits. 
The resulting antiserum was tested in an immu- 
noprecipitation with [ 35S]methionine-labeled induc- 
ed P3HRl cell extract (not shown). Only ep138 
reacts specifically with the rabbit antiserum, which is 
further proof for the correct expression of this pro- 
tein. 
Preliminary experiments indicate the value of the 
pUCARG1140-encoded protein as antigen in the 
diagnostic of EBV-related diseases of NPC (in pre- 
paration). 
The antigen encoded by pUCARGll40 is only a 
first step in generating a complete set of proteins 
covering all necessary antigens for EBV diagnosis. 
Beside ep138, we have expressed another early pro- 
tein, a VCA protein, a nuclear antigen and the major 
membrane protein of EBV (in preparation). 
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